Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

• Published in: Clinical infectious diseases 2021-07, Vol.73 (2), p.195-202
• Main Authors: Atkinson, Andrew, Zwahlen, Marcel, Barger, Diana, d’Arminio Monforte, Antonella, De Wit, Stephane, Ghosn, Jade, Girardi, Enrico, Svedhem, Veronica, Morlat, Philippe, Mussini, Cristina, Noguera-Julian, Antoni, Stephan, Christoph, Touloumi, Giota, Kirk, Ole, Mocroft, Amanda, Reiss, Peter, Miro, Jose M, Carpenter, James R, Furrer, Hansjakob
• Format: Article
• Language: English
• Subjects: AIDS-Related Opportunistic Infections - prevention & control; CD4 Lymphocyte Count; HIV; HIV Infections - complications; HIV Infections - drug therapy; Humans; Life Sciences; Major and Commentaries; Pneumonia, Pneumocystis - prevention & control; Pragmatic Clinical Trials as Topic; Santé publique et épidémiologie
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciaa615

Abstract Background Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficiency virus (HIV) RNA (≤400 copies/mL), irrespective of CD4 count. Methods We implemented an established causal inference approach whereby observational data are used to emulate a randomized trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their CD4 count was ≤200 cells/µL in line with existing recommendations. We compared the following 2 strategies for stopping prophylaxis: (1) when CD4 count was >200 cells/µL for >3 months or (2) when the patient was virologically suppressed (2 consecutive HIV RNA ≤400 copies/mL). Patients were artificially censored if they did not comply with these stopping rules. We estimated the risk of primary PcP in patients on ART, using the hazard ratio (HR) to compare the stopping strategies by fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias introduced by the artificial censoring. Results A total of 4813 patients (10 324 person-years) complied with eligibility conditions for the emulated trial. With primary PcP diagnosis as an endpoint, the adjusted HR (aHR) indicated a slightly lower, but not statistically significant, different risk for the strategy based on viral suppression alone compared with the existing guidelines (aHR, .8; 95% confidence interval, .6–1.1; P = .2). Conclusions This study suggests that primary PcP prophylaxis might be safely withheld in confirmed virologically suppressed patients on ART, regardless of their CD4 count. Using observational data from COHERE, we emulated a randomized trial that showed that primary pneumocystis pneumonia prophylaxis can be safely withdrawn in virologically suppressed patients on antiretroviral therapy, irrespective of the CD4 count.